1. Home
  2. Courses
  3. Course Details Page
Skip to content
eLearning on BoehringerOne
Visit BoehringerOne.com

Hypertension and macrovascular risk: Minimising CV risk at home and at work

Presenters

Richard Henry P. Tiongco II, MD, FPCP, FPCC
Clinical Associate Professor
Richard Henry P. Tiongco II, MD, FPCP, FPCC
View Profile

  • 36 Mins 15 Secs

  • Self paced

    Upon completion you will earn a certificate

Start this course

Course Details

Hypertension is a major risk factor in the development of macrovascular diseases, such as coronary artery disease and stroke. In this webinar, Dr. Richard Henry Tiongco (Philippine General Hospital) explained the pathophysiology of macrovascular disease and the role of hypertension. He also discussed the impact of RAAS blockade in the management of CV risk in patients with HPN and macrovascular disease.

Estimated time of Completion: 36 mins. and 15 secs.

CPD Points: 0.75 Point

PRC Program No: PROG-2022-49927

Hypertension and macrovascular risk: Minimising CV risk at home and at work Course Outline

  • PRESYON 4
  • Impact of Hypertension
  • Vicious circles of large and small artery alterations in hypertension
  • Mechanisms of cardiac damage in essential hypertension
  • Mechanisms of brain damage in essential hypertension
  • SPRINT MIND trial
  • STEP Trial
  • 2020 ISH Simplified Classification of Hypertension Risk
  • Initiation of Treatment
  • 2020 Philippine Hypertension CPG
  • BP Levels recommendation in Patients with Stroke (ECR 2019)
  • Telmisartan: ARB developed by Boehringer Ingelheim
  • Pharmacological Profile of Telmisartan
  • Cellular pathways contributing to LVH in HHD
  • Molecular effect of telmisartan on rat cardiomyocytes
  • Histologic effect of telmisartan on rat cardiomyocytes
  • Telmisartan’s Long Duration of Effect
  • Changes in coronary plaque (IB-IVUS) in telmisartan-treated patients
  • Coronary sinus cytokine levels in telmisartan-treated patients
  • Endothelial dysfunction after coronary DES in telmisartan-treated hypertensive patients
  • Heart Outcomes Prevention Evaluation (HOPE) Study
  • Meta-analysis of antihypertensive agents in patients with established CVD
  • ONTARGET: Telmisartan is As Effective As Ramipril in Preventing CV Events at Increased CV Risk 
  • LV structure and function in telmisartan-treated hypertensives
  • Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS)
  • Telmisartan is As Effective As Ramipril in Preventing CV Events at Increased CV Risk 
  • Holistic treatment of cardiovascular disease
  • Summary

PC-PH-104291 / October 2022